The FDA announced that effective April 7, 2005, Pfizer Inc. was voluntarily withdrawing Bextra at the request of the Food and Drug Administration.
Pfizer stated that, “For now, patients should stop taking Bextra and contact their physicians about appropriate treatment options.”
The FDA has also asked Pfizer to include a boxed warning in the Celebrex label. Until this boxed warning appears however, pharmacists should advise cardholders of the potential for increased risk of cardiovascular events and gastrointestinal bleeding associated with the use of prescription NSAIDs.
Cardholders should also be encouraged to read the Patient Information Sheet included with their medication.
Providers are advised that the Program anticipates placing increased restrictions on the dispensing of Celebrex.
Providers wishing more information about Bextra or Celebrex should access Pfizer Inc.’s website at: